Why the study?
The study aimed to observe the impacts of the specific cyclooxygenase-2 inhibitor celecoxib on cardiac structures, functions, and inflammatory factors during pressure overload-induced myocardial hypertrophy.
Does celecoxib improve cardiac structure and function in a rat model of pressure overload-induced myocardial hypertrophy?
RCT (n=24)
randomly divided
Does celecoxib improve cardiac structure and function in a rat model of pressure overload-induced myocardial hypertrophy?
p-value: p=< .05
In a rat model of pressure overload, celecoxib attenuated myocardial hypertrophy and improved cardiac function, suggesting a role for inflammatory pathways in hypertrophy.
Hypothesis-generating for celecoxib in rat pressure-overload hypertrophy; leaves open human translation.
OBJECTIVE: The aim of this study was to observe the impacts of the specific cyclooxygenase-2 inhibitor celecoxib on cardiac structures, functions, and inflammatory factors during the process of pressure overload-induced myocardial hypertrophy. METHODS: Twenty-four male Sprague Dawley rats were randomly divided into 3 groups: the sham operation group, the surgery group, and the celecoxib group. The model was established according to the abdominal aortic coarctation method. RESULTS: At 16 weeks, rats in the celecoxib group were fed a celecoxib-mixed diet (10 mg/kg) for 8 consecutive weeks. At week 24 after model establishment, the cardiac structures and functions were observed; changes in the levels of tumor necrosis factor (TNF)-α, transforming growth factor (TGF)-β, prostaglandin E2 (PGE2), C-reactive protein (CRP), and uric acid (UA) were detected; and the contents of Smad1/2/3 proteins (Smad1, Smad2, and Smad3) were determined. Left ventricular mass index, the heart weight/body weight ratio, and TNF-α, TGF-β, PGE2, CRP, and UA levels of the celecoxib group were all significantly decreased relative to those of the surgery group (P < .05); moreover, the cardiac functions were significantly improved compared to those of the surgery group (P < .05). CONCLUSIONS: These results show that inflammatory factors are involved in the myocardial hypertrophy process and that celecoxib may reverse myocardial hypertrophy through a variety of pathways.
No takes yet. Share an insight, caveat, or question.
Xie et al. (2019) conducted an RCT in pressure overload-induced myocardial hypertrophy (n=24). celecoxib vs. surgery group and sham operation group was evaluated on Left ventricular mass index, heart weight/body weight ratio, inflammatory factors, and cardiac functions (p=< .05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: